Sugi Predict

Sugi Predict / Compounds / SCHEMBL4896010

SCHEMBL4896010

SCHEMBL4896010

O=Cc1c(Cl)cc(OS(=O)(=O)C(F)(F)F)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ EPAS1 Q99814 5/20 0.35
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ HTR1D P28221 3/20 0.32
▸ HTR1A P08908 2/20 0.32
▸ HTR1B P28222 2/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ HSD11B1 P28845 1/20 0.31
▸ CXCR2 P25025 2/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE4C Q08493 1/20 0.31
▸ PDE4D Q08499 1/20 0.31
▸ PGR P06401 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3045676 0.80 TDP1 (0.46) ALDH1A1TDP1ADORA2AADORA1EPAS1
SCHEMBL18106651 0.79 HTR1A (0.35) ADORA2AADORA1EPAS1CA1CA2
SCHEMBL28741449 0.79 ADORA2A (0.37) ALDH1A1ADORA2AADORA1EPAS1CA1
SCHEMBL1252245 0.78 CXCR2 (0.34) ADORA2AADORA1EPAS1CA1CA2
SCHEMBL926505 0.77 CA2 (0.41) ADORA2AADORA1CA1CA2HTR1D
SCHEMBL12581686 0.77 EPAS1 (0.32) ALDH1A1EPAS1
SCHEMBL1039808 0.77 MEN1 (0.40) MEN1ALDH1A1KMT2ATDP1EPAS1
SCHEMBL16664708 0.77 STS (0.37) ADORA2AADORA1CA1CA2HTR1D
SCHEMBL8444519 0.76 ADORA2A (0.49) ADORA2AADORA1EPAS1CA1CA2
SCHEMBL22444882 0.74 ADORA2A (0.34) ADORA2AADORA1EPAS1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528761-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
EP-4168384-A1 THYROMIMETICS Autobahn Therapeutics, Inc. (US) 2023-04-26 — — EP disclosed
CN-115916740-A Thyromimetic agents 速通医疗公司 2023-04-04 — — CN disclosed
WO-2021257851-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 — — WO disclosed
WO-2021257851-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 — — WO disclosed
US-20190330157-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2019-10-31 — — US disclosed
EP-1499577-B1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES HOFFMANN LA ROCHE (CH) 2007-05-30 — — EP disclosed
EP-1620392-A2 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS Wyeth (US) 2006-02-01 — — EP disclosed
US-6946471-B2 2-(2,6-Dichlorophenyl)-Diarylimidazoles HOFFMANN-LA ROCHE INC. (US) 2005-09-20 — — US disclosed
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents WYETH 2005-01-27 — — US disclosed
EP-1499577-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-26 — — EP disclosed
WO-2004099122-A2 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH (US) 2004-11-18 — — WO disclosed
US-20040214874-A1 2-(2,6-Dichlorophenyl)-Diarylimidazoles BRANDT MICHAEL 2004-10-28 — — US disclosed
US-6790852-B2 HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-09-14 — — US disclosed
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — US disclosed
WO-2003087026-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330157-A1 THERAPEUTIC COMPOUNDS OPRL1, INA, OGFR MEN1 4058/4885ALDH1A1 1048/4885KMT2A 3083/4885
US-20050020676-A1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents ESR1, ESR2, ESRRB MEN1 3310/4885ALDH1A1 348/4885KMT2A 258/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR MEN1 4058/4885ALDH1A1 1048/4885KMT2A 3083/4885
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles CYP2D6, CYP2F1, CYP1A2 MEN1 1726/4885ALDH1A1 115/4885KMT2A 933/4885
US-20040214874-A1 2-(2,6-Dichlorophenyl)-Diarylimidazoles CYP2D6, CYP1A2, CYP2F1 MEN1 1918/4885ALDH1A1 89/4885KMT2A 858/4885
US-12528761-B2 Thyromimetics TSHR, THRB, TTR MEN1 1741/4885ALDH1A1 1038/4885KMT2A 3776/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB MEN1 708/4885ALDH1A1 1458/4885KMT2A 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.